AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Shares of Amylyx Pharmaceuticals AMLX surged 63.8% yesterday after it announced positive top-line data from the phase III LUCIDITY study. This study evaluated its lead candidate, avexitide, a GLP-1 receptor antagonist, in participants with post-bariatric hypoglycemia (“PBH”), following Roux-en-Y gastric bypass surgery.

Year to date, shares of Amylyx have rallied 190.7% against the industry’s decline of 0.8%.

Image Source: Zacks Investment Research

More on AMLX’s Latest LUCIDITY Study Data

The double-blind, placebo-controlled phase III LUCIDITY study met its FDA-agreed primary endpoint, with avexitide reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% compared with placebo through week 16.

The LUCIDITY study also met all secondary endpoints, showing statistically significant reductions in Level 2 events measured by self-monitoring of blood glucose and continuous glucose monitoring, as well as independently adjudicated Level 3 events.

Treatment with avexitide was generally well tolerated, with most adverse effects being mild to moderate and no serious adverse effects related to treatment reported.

The LUCIDITY study enrolled 78 adults with PBH following Roux-en-Y gastric bypass surgery. Participants were randomized 3:2 to receive either avexitide (90 mg) subcutaneously once daily or placebo.

AMLX Eyes 2026-End Regulatory Filing for Avexitide

Management noted that the latest results from the LUCIDITY study, together with data from five earlier clinical studies, support avexitide’s potential as the first approved treatment for PBH.

Per the company, PBH is a chronic metabolic condition that can cause recurrent episodes of dangerously low blood sugar levels. The condition currently has no FDA-approved treatment, creating a significant unmet medical need.

Amylyx plans to submit a new drug application (“NDA”) for avexitide to treat PBH to the FDA by the end of 2026.

The FDA has already granted a Breakthrough Therapy designation to avexitide for treating PBH.

If approved, Amylyx aims to launch avexitide commercially in 2027. This would give the company its first marketed drug and a potential recurring source of product revenues.

Amylyx is also exploring avexitide in congenital hyperinsulinism.

AMLX’s Zacks Rank & Stocks to Consider

Amylyx currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the drug/biotech sector are Repligen RGEN, Anika Therapeutics ANIK and Amneal Pharmaceuticals AMRX, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61 during the same time. RGEN’s shares have gained 1.4% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for Anika Therapeutics’ 2026 earnings per share have risen from 41 cents to $1.05, while estimates for 2027 have increased from 46 cents to 95 cents during the same time. ANIK’s shares have surged 124.5% year to date.

Anika Therapeutics’ earnings beat estimates in each of the trailing three quarters, with the average surprise being 950.00%.

Over the past 60 days, estimates for Amneal’s 2026 earnings per share have risen from $1.00 to $1.02, while estimates for 2027 have increased from $1.12 to $1.21 during the same time. AMRX’s shares have rallied 44.4% year to date.

Amneal’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 32.82%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research